The use of cephalosporins for gonorrhea: An update on the rising problem of resistance

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 10, 2012, Pages 1411-1420

  Stoltey, Juliet E ^a   Barry, Pennan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cephalosporin resistance; Neisseria gonorrhoeae

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; DOXYCYCLINE; ERTAPENEM; EXTENDED SPECTRUM CEPHALOSPORIN DERIVATIVE; GEMIFLOXACIN; GENTAMICIN; SOLITHROMYCIN; SPECTINOMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; DRUG SURVEILLANCE PROGRAM; DRUG TREATMENT FAILURE; GONORRHEA; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NONHUMAN; PERSONALIZED MEDICINE; PHARYNGEAL GONORRHEA; PHARYNGITIS; PUBLIC HEALTH SERVICE; RECOMMENDED DRUG DOSE; REVIEW; WORLD HEALTH ORGANIZATION;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; GONORRHEA; HUMANS; POPULATION SURVEILLANCE;

EID: 84863085766     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.690396     Document Type: Review

References (81)

1. Barry PM, Klausner JD. the use of cephalosporins for gonorrhea: The impending problem of resistance. Expert Opin Pharmacother 2009;10:555-77
2. Unemo M, Golparian D, Nicholas R, et al. High-level cefixime- and ceftriaxone-resistant N. gonorrhoeae in Europe (France): novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2011;published online 12 December 2011; doi:10.1128/AAC.05760- 11
3. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011;55:3538-45
4. Unemo M, Shafer WM. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann NY Acad Sci 2011;1230:E19-28
5. Dillon JA. Sustainable antimicrobial surveillance programs essential for controlling Neisseria gonorrhoeae superbug. Sex Transm Dis 2011;38:899-901
6. World Health Organization Department of Reproductive Health and Research. Emergence of multi-drug resistant Neisseria gonorrhoeae - Threat of global rise in untreatable sexually transmitted infections. 2011. Available from: http://www.who.int/reproductivehealth/publications/rtis/who-rhr-11-14/en/index. html [Last accessed 19 December 2011]
7. Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009;7:821-34
8. World Health Organization Department of Reproductive Health and Research. Prevalence and incidence of selected sexually transmitted infections: Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis. Methods and results used by WHO to generate 2005 estimates. 2011. Available from: http://www.who.int/reproductivehealth/publications/rtis/9789241502450/en/index. html [Last accessed 19 December 2011]
9. Marrazzo JM, Handsfield HH, Sparling PF. Neisseria gonorrhoeae. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th edition. Churchill Livingstone Elsevier; Philadelphia, PA: 2010
10. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: The contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999;75:3-17
11. Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis 2001;28:579-97
12. Ito M, Deguchi T, Mizutani KS, et al. Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in Central Japan. Antimicrob Agents Chemother 2005;49:137-43
13. Tomberg J, Unemo M, Davies C, Nicholas RA. Molecular and structural analysis of mosaic variants of penicillin-binding protein 2 conferring decreased susceptibility to expanded-spectrum cephalosporins in Neisseria gonorrhoeae: Role of epistatic mutations. Biochemistry 2010;49:8062-70
14. Hagman KE, Pan W, Spratt BG, et al. Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system. Microbiology 1995;141:611-22
15. Warner DM, Folster JP, Shafer WM, Jerse AE. Regulation of the MtrC-MtrD-MtrE efflux-pump system modulates the in vivo fitness of Neisseria gonorrhoeae. J Infect Dis 2007;196:1804-12
16. Lindberg R, Fredlund H, Nicholas R, Unemo M. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: Association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother 2007;51:2117-22
17. Gill MJ, Simjee S, Al-Hattawi K, et al. Gonococcal resistance to beta-lactams and tetracycline involves mutation in loop 3 of the porin encoded at the penB locus. Antimicrob Agents Chemother 1998;42:2799-803
18. Golparian D, Hellmark B, Fredlund H, Unemo M. Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden. Sex Transm Infect 2010;86:454-60
19. Zhao S, Duncan M, Tomberg J, et al. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in neisseria gonorrhoeae. Antimicrob Agents Chemother 2009;53:3744-51
20. Unemo M, Fasth O, Fredlund H, et al. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother 2009;63:1142-51
21. Australian Gonococcal Surveillance Programme. Australian gonococcal surveillance programme annual report, 2010. Commun Dis Intell 2011;35:229-36
22. Health Protection Agency. GRASP 2010 Report: The Gonococcal Resistance to Antimicrobials Surveillance Programme. 2011. Available from: http://www.hpa.org.uk/GRASP2010 [Last accessed 28 December 2011]
23. Martin IM, Hoffmann S, Ison CA. European Surveillance of Sexually Transmitted Infections (ESSTI): The first combined antimicrobial susceptibility data for Neisseria gonorrhoeae in Western Europe. J Antimicrob Chemother 2006;58:587-93
24. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 18th Informational Supplement. CLSI document M100-S18, January 2008
25. Yokoi S, Deguchi T, Ozawa T, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007;13:1275-7
26. Deguchi T, Yasuda M, Yokoi S, et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother 2003;9:35-9
27. Lo JY, Ho KM, Leung AO, et al. Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicrob Agents Chemother 2008;52:3564-7
28. Forsyth S, Penney P, Rooney G. Cefixime-resistant Neisseria gonorrhoeae in the UK: A time to reflect on practice and recommendations. Int J STD AIDS 2011;22:296-7
29. Ison CA, Hussey J, Sankar KN, et al. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011;16(14):pii=19833. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId= 19833 [Last accessed 11 May 2012]
30. Unemo M, Golparian D, Stary A, Eigentler A. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill 2011;16(43):pii=19998. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19998 [Last accessed 11 May 2012]
31. Unemo M, Golparian D, Syversen G, et al. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010;15(47):pii=19721. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19721 [Last accessed 11 May 2012]
32. Chisholm SA, Alexander S, Desouza-Thomas L, et al. Emergence of a Neisseria gonorrhoeae clone showing decreased susceptibility to cefixime in England and Wales. J Antimicrob Chemother 2011;66:2509-12
33. Tapsall J, Read P, Carmody C, et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009;58:683-7
34. Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 2011;16(6):pii=19792. Available from: http://www. eurosurveillance.org/ViewArticle.aspx?ArticleId=19792 [Last accessed 11 May 2012]
35. Weinstock H, Workowski KA. Pharyngeal gonorrhea: An important reservoir of infection? Clin Infect Dis 2009;49:1798-800
36. Ota KV, Fisman DN, Tamari IE, et al. Incidence and treatment outcomes of pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis infections in men who have sex with men: A 13-year retrospective cohort study. Clin Infect Dis 2009;48:1237-43
37. Ohnishi M, Saika T, Hoshina S, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis 2011;17:148-9
38. Pandori M, Barry PM, Wu A, et al. Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California. Antimicrob Agents Chemother 2009;53:4032-4
39. Huang CT, Yen MY, Wong WW, et al. Characteristics and dissemination of mosaic penicillin-binding protein 2-harboring multidrug-resistant Neisseria gonorrhoeae isolates with reduced cephalosporin susceptibility in northern Taiwan. Antimicrob Agents Chemother 2010;54:4893-5
40. Allen VG, Farrell DJ, Rebbapragada A, et al. Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada. Antimicrob Agents Chemother 2011;55:703-12
41. Takahata S, Senju N, Osaki Y, et al. Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 2006;50:3638-45
42. Unemo M, Shipitsyna E, Domeika M. Gonorrhoea surveillance, laboratory diagnosis and antimicrobial susceptibility testing of Neisseria gonorrhoeae in 11 countries of the eastern part of the WHO European region. APMIS 2011;119:643-9
43. World Health Organization Department of Reproductive Health and Research. Guidelines for the management of sexually transmitted infections. 2003. Available from: http://www.who.int/reproductivehealth/publications/rtis/ 9241546263/en/index.html [Last accessed 19 December 2011]
44. World Health Organization Department of Reproductive Health and Research. Sexually transmitted and other reproductive tract infections: A guide to essential practice. 2005. Available from: http://www.who.int/reproductivehealth/ publications/rtis/9241592656/en/index. html [Last accessed 19 December 2011]
45. World Health Organization Department of Reproductive Health and Research. Global strategy for the prevention and control of sexually transmitted infections: 2006 - 2015. Breaking the chain of transmission. 2007. Available from: http://www.who.int/reproductivehealth/publications/rtis/9789241563475/en/ index.html [Last accessed 19 December 2011]
46. Tapsall JW. Implications of current recommendations for third-generation cephalosporin use in the WHO western pacific region following the emergence of multiresistant gonococci. Sex Transm Infect 2009;85:256-8
47. Unemo M, Shipitsyna E, Domeika M. Recommended antimicrobial treatment of uncomplicated gonorrhoea in 2009 in 11 East European countries: Implementation of a Neisseria gonorrhoeae antimicrobial susceptibility programme in this region is crucial. Sex Transm Infect 2010;86:442-4
48. Bignell C. 2009 European (IUSTI/WHO) guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2009;20:453-7
49. Bignell C, Fitzgerald M. UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS 2011;22:541-7
50. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010;59:1-110
51. Centers for Disease Control and Prevention. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates - United States, 2000 - 2010. MMWR Morb Mortal Wkly Rep 2011;60:873-7
52. Morris SR, Klausner JD, Buchbinder SP, et al. Prevalence and incidence of pharyngeal gonorrhea in a longitudinal sample of men who have sex with men: The EXPLORE study. Clin Infect Dis 2006;43:1284-9
53. Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis 2005;41:67-74
54. Linhart Y, Shohat T, Amitai Z, et al. Sexually transmitted infections among brothel-based sex workers in Tel-Aviv area, Israel: high prevalence of pharyngeal gonorrhoea. Int J STD AIDS 2008;19:656-9
55. Bernstein KT, Stephens SC, Barry PM, et al. Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the oropharynx to the urethra among men who have sex with men. Clin Infect Dis 2009;49:1793-7
56. Ameyama S, Onodera S, Takahata M, et al. Mosaic-like structure of penicillin-binding protein 2 Gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob Agents Chemother 2002;46:3744-9
57. Knapp JS, Hook EW III. Prevalence and persistence of Neisseria cinerea and other Neisseria spp. in adults. J Clin Microbiol 1988;26:896-900
58. Kinghorn G. Pharyngeal gonorrhoea: A silent cause for concern. Sex Transm Infect 2010;86:413-14
59. Whiley DM, Tapsall JW, Sloots TP. Nucleic acid amplification testing for Neisseria gonorrhoeae: An ongoing challenge. J Mol Diagn 2006;8:3-15
60. Goire N, Ohnishi M, Limnios AE, et al. Enhanced gonococcal antimicrobial surveillance in the era of ceftriaxone resistance: A real-time PCR assay for direct detection of the Neisseria gonorrhoeae H041 strain. J Antimicrob Chemother 2012;67:902-5
61. Unemo M, Dillon JA. Review and international recommendation of methods for typing neisseria gonorrhoeae isolates and their implications for improved knowledge of gonococcal epidemiology, treatment, and biology. Clin Microbiol Rev 2011;24:447-58
62. Chisholm SA, Mouton JW, Lewis DA, et al. Cephalosporin MIC creep among gonococci: Time for a pharmacodynamic rethink? J Antimicrob Chemother 2010;65:2141-8
63. Ross JD, Lewis DA. Cephalosporin resistant Neisseria gonorrhoeae: Time to consider gentamicin? Sex Transm Infect 2012;88:6-8
64. Kirkcaldy RD, Ballard RC, Dowell D. Gonococcal resistance: Are cephalosporins next? Curr Infect Dis Rep 2011;13:196-204
65. Lewis DA, Lukehart SA. Antimicrobial resistance in Neisseria gonorrhoeae and Treponema pallidum: evolution, therapeutic challenges and the need to strengthen global surveillance. Sex Transm Infect 2011;87(Suppl 2):39-43
66. Muratani T, Inatomi H, Ando Y, et al. Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol 2008;15:837-42
67. Tanaka M. Emergence of multidrug-resistant Neisseria gonorrhoeae strains circulating worldwide. Int J Urol 2011. [Epub ahead of print]
68. Jaffe HW, Schroeter AL, Reynolds GH, et al. Pharmacokinetic determinants of penicillin cure of gonococcal urethritis. Antimicrob Agents Chemother 1979;15:587-91
69. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995;20(Suppl 1):47-65
70. Workowski KA, Berman SM, Douglas JM Jr. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med 2008;148:606-13
71. Katz AR, Komeya AY, Soge OO, et al. Neisseria gonorrhoeae with high-level resistance to azithromycin: Case report of the first isolate identified in the United States. Clin Infect Dis 2011;published online 19 Dec 2011; doi:10.1093/cid/cir929
72. National Institute of Allergy and Infectious Diseases (NIAID). Efficacy of Combination Therapies for Gonorrhea Treatment. ClinicalTrialsgov, 2010. Available from: http://clinicaltrials. gov/ct2/show/NCT00926796 NLM Identifier: NCT00926796 [Last accessed 2 February 2012]
73. Livermore DM, Alexander S, Marsden B, et al. Activity of ertapenem against Neisseria gonorrhoeae. J Antimicrob Chemother 2004; 54:280-1
74. Chisholm SA, Quaye N, Cole MJ, et al. An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe. J Antimicrob Chemother 2011; 66:592-5
75. Gil-Setas A, Navascues-Ortega A, Beristain X. Spectinomycin in the treatment of gonorrhoea. Euro Surveill 2010;15(19):pii/19568-author reply pii/69
76. Golparian D, Fernandes P, Ohnishi M, et al. in vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea? Antimicrob Agents Chemother 2012;56:2739-42
77. Limnios A, Tapsall J, Kahlmeter J, et al. Cefpodoxime 10 mcg disc screening test for detection of Neisseria gonorrhoeae with mosaic PBP2 and decreased susceptibility to extended-spectrum cephalosporins for public health purposes. APMIS 2011;119:356-63
78. Dowell D, Tian LH, Stover JA, et al. Changes in fluoroquinolone use for gonorrhea following publication of revised treatment guidelines. Am J Public Health 2011;published online 28 Nov 2011; doi:10.2105/AJPH.2011.300283
79. WHO Western Pacific and South East Asian Gonococcal Antimicrobial Surveillance Programmes. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific and South East Asian Regions, 2009. Commun Dis Intell 2011;35:2-7
80. Kubanova A, Frigo N, Kubanov A, et al. the Russian gonococcal antimicrobial susceptibility programme (RU-GASP) - national resistance prevalence in 2007 and 2008, and trends during 2005 - 2008. Euro Surveill 2010;15(14):pii=19533. Available from: http://www.eurosurveillance.org/ ViewArticle.aspx?ArticleId=19533 [Last accessed 11 May 2012]
81. Cole MJ, Unemo M, Hoffmann S, et al. the European gonococcal antimicrobial surveillance programme, 2009. Euro Surveill 2011;16(42):pii=19995. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId= 19995 [Last accessed 11 May 2012]